Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan in the Treatment of Hypertensive Patients with Metabolic Syndrome
2005-000614-12Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of irbesartan in hypertension (HTN) and cardiometabolic risk (CMR) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change in insulin resistance by Matsuda Index. Started Oct 2005; status: completed.
02
Drugs
irbesartan
03
Conditions
hypertension (HTN)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2005-000614-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000614-12.